You can view polls created in the following languages.
English
German
French
Spanish
Dutch
Romanian
Norwegian
Portugese
Serbo Croatian
Arabic

Regulatory approval of New Molecular Entities (NMEs) is at a record-low pace for 2008. To what do you attribute this?

Due to safety concerns, the FDA and EMEA are being overly cautious.

Reviewers at the regulatory agencies are overworked and understaffed.

The biopharmaceutical industry is suffering from a severe lack of innovation.

None of the above.

Comments have been disabled for this poll.